Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Marmelosin is a natural furanocoumarin bioactive constituent derived from the Indian medicinal plant *Aegle marmelos* (Bael). It is primarily investigated for its neuroprotective, antioxidant, and anti-inflammatory properties. In preclinical models of Parkinson's disease, marmelosin has demonstrated the ability to ameliorate 6-OHDA-induced cognitive impairment and dopaminergic neuronal loss. Its mechanism of action involves the upregulation of the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) signaling pathway, which leads to a reduction in pro-apoptotic markers such as activated caspase-3 and the Bax/Bcl-2 ratio.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on marmelosin.